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Abstract We report an extensive study of variability
in genes encoding proteins that are believed to be
involved in the action and biotransformation of warfa-
rin. Warfarin is a commonly prescribed anticoagulant
that is diYcult to use because of the wide interindivid-
ual variation in dose requirements, the narrow thera-
peutic range and the risk of serious bleeding. We
genotyped 201 patients for polymorphisms in 29 genes
in the warfarin interactive pathways and tested them for
association with dose requirement. In our study, poly-
morphisms in or Xanking the genes VKORC1, CYP2C9,
CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU,
GGCX and ORM1-ORM2 and haplotypes of
VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7,
GGCX, PROZ, F9, NR1I2 and ORM1-ORM2 were
associated with dose (P < 0.05). VKORC1, CYP2C9,
CYP2C18 and CYP2C19 were signiWcant after
experiment-wise correction for multiple testing
(P < 0.000175), however, the association of CYP2C18
and CYP2C19 was fully explained by linkage disequilib-
rium with CYP2C9*2 and/or *3. PROC and APOE
were both signiWcantly associated with dose after cor-
rection within each gene. A multiple regression model
with VKORC1, CYP2C9, PROC and the non-genetic
predictors age, bodyweight, drug interactions and indi-
cation for treatment jointly accounted for 62% of vari-
ance in warfarin dose. Weaker associations observed
for other genes could explain up to »10% additional
dose variance, but require testing and validation in an
independent and larger data set. Translation of this
knowledge into clinical guidelines for warfarin prescrip-
tion will be likely to have a major impact on the safety
and eYcacy of warfarin.
Abbreviations
ABCB1 ATP-binding cassette transporter B1 
gene, P-glycoprotein gene or MDR1
APOE Apolipoprotein E
CALU Calumenin gene
CAR Constitutive androstane receptor
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CYP1A2 Cytochrome P450 1A2
CYP2A6 Cytochrome P450 2A6
CYP2C18 Cytochrome P450 2C18
CYP2C19 Cytochrome P450 2C19
CYP2C8 Cytochrome P450 2C8
CYP2C9 Cytochrome P450 2C9
CYP3A4 Cytochrome P450 3A4
CYP3A5 Cytochrome P450 3A5
EPHX1 Epoxide hydrolase 1, microsomal gene
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24 Hum Genet (2007) 121:23–34F2 Coagulation factor II gene or prothrom
bin gene
F5 Coagulation factor V gene
F7 Coagulation factor VII gene
F9 Coagulation factor IX gene
F10 Coagulation factor X gene
FII Coagulation factor II or prothrombin
FIIa Coagulation factor II activated or 
thrombin
FIX Coagulation factor IX
FIXa Coagulation factor IX activated
FV Coagulation factor V
FVII Coagulation factor VII
FVIIa Coagulation factor VII activated
FX Coagulation factor X
FXa Coagulation factor X activated
GAS6 Growth-arrest speciWc 6
GGCX Gamma-glutamyl carboxylase gene
MDR1 Multidrug resistance gene 1, P-glycopro
tein gene or ABCB1
NQO1 NAD(P)H dehydrogenase, 
quinone 1 gene
NR1I2 Pregnane X receptor gene
NR1I3 Constitutive androstane receptor gene
ORM1 Orosomucoid 1 gene or Alpha-1-acid 
glycoprotein 1 gene
ORM2 Orosomucoid 2 gene or Alpha-1-acid 
glycoprotein 2 gene
PCR Polymerase chain reaction
PROC Protein C gene
PROS1 Protein S gene
PROZ Protein Z gene
PT INR Prothrombin time international norma
lised ratio
PXR Pregnane X receptor
SERPINC1 Anti-thrombin III gene
siRNA Small interfering ribonucleic acid
SNP Single nucleotide polymorphism
UTR Untranslated region
VKORC1 Vitamin K epoxide reductase 
complex subunit 1 gene
Background
Warfarin is one of the most widely used coumarin anti-
coagulants in the treatment of atrial Wbrillation, heart
valve prosthesis, recurrent stroke, deep vein thrombo-
sis and pulmonary embolism (Daly and King 2003).
However, its use is made diYcult by the wide interindi-
vidual variation in dose required to achieve a therapeu-
tic eVect, the narrow therapeutic range, and the risk of
serious bleeding (Landefeld and Beyth 1993). Warfarin
dose requirement, which varies 20-fold, is inXuenced
by factors such as intake of vitamin K, ethnicity, illness,
age, gender, concurrent medication, body mass index
and genetic factors (Loebstein et al. 2001; Takahashi
and Echizen 2003; Wadelius et al. 2004).
Warfarin acts through interference with the recy-
cling of vitamin K in the liver, which leads to secretion
of inactive vitamin K-dependent proteins (Bell et al.
1972; Dahlbäck 2005). Figure 1 shows the genes that
are believed to be involved in the biotransformation of
vitamin K, warfarin and the vitamin K-dependent clot-
ting factors, here called the warfarin interactive path-
ways (Supplementary Table S1; for details see
Wadelius and Pirmohamed 2006). The main protein in
the vitamin K epoxide reductase complex is encoded
by VKORC1 (Li et al. 2004; Rost et al. 2004). Common
variation in human VKORC1 is one of the most impor-
tant genetic factors determining warfarin dose
(D’Andrea et al. 2005; Geisen et al. 2005; Rieder et al.
2005; Sconce et al. 2005; Wadelius et al. 2005; Veenstra
et al. 2005; Yuan et al. 2005). Another putative subunit
of the vitamin K epoxide reductase is the microsomal
epoxide hydrolase 1, encoded by EPHX1, which har-
bours a vitamin K-epoxide binding site (Cain et al.
1997; Loebstein et al. 2005; Morisseau and Hammock
2005). Calumenin, encoded by CALU, binds to vitamin
K epoxide reductase and inhibits the eVect of warfarin
(Wallin et al. 2001; Wajih et al. 2004).
A high intake of the fat-soluble vitamin K1 can
reverse the action of warfarin. Vitamin K1 is absorbed
from the small intestine along with dietary fat, and sub-
sequently cleared by the liver through an apolipopro-
tein E (APOE) receptor speciWc uptake (Berkner and
Runge 2004). The uptake of vitamin K1 into the liver
varies between diVerent APOE alleles and is in the
order of *E2 < *E3 < *E4 (Saupe et al. 1993; Kohlme-
ier et al. 1996). It has also been suggested that the anti-
oxidant enzyme nicotine adenine dinucleotide
phosphate (NAD(P)H) dehydrogenase, encoded by
NQO1, has the potential to reduce dietary vitamin K
(Wallin and Hutson 1982; Berkner and Runge 2004).
Reduced vitamin K is the essential cofactor for the
activation of vitamin K-dependent proteins by gamma-
glutamyl carboxylase, encoded by GGCX (Wu et al.
1997; Berkner 2000). The main vitamin K-dependent
proteins are clotting factors II, VII, IX and X, proteins
C, S and Z, and the growth-arrest speciWc protein 6,
encoded by F2, F7, F9, F10, PROC, PROS1, PROZ
and GAS6, respectively (Berkner and Runge 2004). A
non-vitamin K-dependent clotting protein anti-thrombin
III, encoded by SERPINC1, inhibits the vitamin K-
dependent factors II, IX and X (Dahlbäck 2005).
Furthermore, the point mutation Arg506Gln (FV Leiden)123
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therefore a known cause of warfarin treatment (Larsen
et al. 1998).
The molecular basis of warfarin pharmacokinetics
has been extensively studied (Sanderson et al. 2005).
Warfarin is administered as a racemate that consists of
R- and S-enantiomers, the S-form being 3–5 times
more active than the R-form (Rettie et al. 1992). War-
farin is rapidly absorbed from the stomach and the
upper gastrointestinal tract (Palareti and Legnani
1996), and in the circulating blood it is highly bound to
albumin and alpha 1-acid glycoproteins, encoded by
ORM1 and ORM2 (Otagiri et al. 1987). Once warfarin
has entered the liver, S-warfarin is metabolised by
cytochrome P450 2C9 (CYP2C9) (Rettie et al. 1992;
Kaminsky and Zhang 1997). Patients with CYP2C9
variant alleles *2 and *3 alleles (http://www.imm.ki.se/
CYPalleles/) require lower mean daily warfarin doses
than extensive metabolisers homozygous for the *1
wild type allele do, and may have a greater risk of
bleeding, especially during the induction of therapy
(Sanderson et al. 2005). The enzymes CYP2C8,
CYP2C18, CYP2C19 may also play a role in the
metabolism of S-warfarin (Rettie et al. 1992; Kaminsky
and Zhang 1997). R-warfarin is mainly metabolised
by CYP1A2 and CYP3A4 (Rettie et al. 1992; Zhang
et al. 1995; Kaminsky and Zhang 1997). In addition,
CYP1A1, CYP2C8, CYP2C18, CYP2C19 and CYP3A5
may be involved in the metabolism of R-warfarin
(Rettie et al. 1992; Zhang et al. 1995; Kaminsky and
Zhang 1997; Huang et al. 2004). Cytochrome P450
enzymes are induced by the nuclear hormone receptors
pregnane X receptor (PXR) and constitutive andro-
stane receptor (CAR), which are encoded by NR1I2
and NR1I3 (Lehmann et al. 1998; Chen et al. 2004).
Based on an inhibition assay, there is some evidence
that transport of warfarin out of the liver and into the
bile may be mediated by P-glycoprotein, which
is encoded by ABCB1 (MDR1) (Sussman et al. 2002).
P-glycoprotein can be induced by the nuclear hormone
receptor PXR (Geick et al. 2001).
We and others have shown that common variants in
the VKORC1 and CYP2C9 genes together with a lim-
ited subset of environmental determinants account for
around 50–60% of the variance in warfarin dose
requirement (Sconce et al. 2005; Wadelius et al. 2005;
Veenstra et al. 2005; Aquilante et al. 2006; Lee et al.
2006; Takahashi et al. 2006; Vecsler et al. 2006). Here,
we Wne map the VKORC1 and the CYP2C gene cluster
loci on chromosomes 16 and 10, respectively, and
assess common variation in 27 other genes in the war-
farin interactive pathways for association with dose
requirements. Finally, we evaluate the potential contri-
bution of all positively associated genes to a warfarin
dose model, which includes age, bodyweight, concomi-
tant medication and indication for treatment.
Fig. 1 An overview of the 
interaction between warfarin 
and the 29 genes. This path-
way illustrates genes thought 
to mediate the eVects of war-
farin. It also depicts a simpli-
Wed representation of the 
biotransformation of warfarin 
and vitamin K123
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Subjects
Two hundred and one Caucasian patients were
recruited at Uppsala University Hospital in 2000; 194
patients of Swedish origin, four of other European
descent and three from the Middle East (Wadelius
et al. 2004). Their mean age was 66.7 years (range 28–
88 years), and 1/3 of them were women. They had been
treated with warfarin (Waran®, Nycomed AB, Stock-
holm, Sweden) for a minimum of 2 months (range
2.4 months–26 years, median 2 years), and their pro-
thrombin time international normalised ratio (PT
INR) had been stabilised. At the six following visits,
Wve weekly warfarin doses and Wve corresponding PT
INR were registered. Individual warfarin dose require-
ment ranged from 4.5 to 77.25 mg/week. Information
about age, gender, bodyweight (missing in seven
patients), treatment indication and duration, other dis-
eases and concurrent medication was taken from the
patients’ medical records, and the details have been
presented previously (Wadelius et al. 2004, 2005).
Patients were stratiWed into two groups depending on
indication for treatment: patients with heart valve
prosthesis (n = 49), where a higher target INR usually
is recommended, and patients treated for other indica-
tions such as atrial Wbrillation (n = 113), thromboem-
bolic disease (n = 9), cardiomyopathy (n = 8) and
transischemic attack (n = 5). Concurrent medications
were registered, and drugs were classiWed as interact-
ing if they had moderate or major interactions with
warfarin according to the database MICROMEDEX®
Healthcare Series (http://www.micromedex.com/)
(May 2002). The patients had a total of 107 concurrent
medications known to inXuence warfarin. They were
divided into three groups: individuals with drugs that
lower the eVect of warfarin by inducing its metabolism
(n = 4), those with medications that potentiate the
eVect of warfarin (n = 74) and patients without any
known interactions (n = 123). The study was approved
by the local Ethics Committee.
Genotyping
DNA was extracted from whole blood using QIAamp®
DNA Blood Mini Kit (QIAGEN Ltd., Crawley, UK).
Within the 29 candidate genes including 5 kb up- and
downstream Xanking regions, we selected available sin-
gle nucleotide polymorphisms (SNPs), preferably with
minor allele frequency (MAF) > 5% and spread out as
evenly as possible every 2–5 kb. The Wrst set of SNPs
was selected from dbSNP (http://www.ncbi.nlm.nih.
gov/projects/SNP/) prior to the HapMap (http://www.
hapmap.org/index.html.en), which was later used for
gap Wlling in regions where the tested SNPs failed or
were monomorphic in our population. In addition, we
mined functional polymorphisms from the literature. In
the process circa 900 SNPs were tested. SNP assays were
designed with the SpectroDESIGNER™ software.
The GGCX microsatellite marker in intron 6 was
analysed as described earlier (Chen et al. 2005). SNP
typing was performed with the Homogeneous Mass
Extend assay (Sequenom, Hamburg, Germany). Poly-
merase chain reaction (PCR) ampliWcation was per-
formed in 5-L reactions using 3.5 ng DNA and
150 nM of each forward and reverse primer, 200 M
deoxynucleotide triphosphates (dNTPs), 1 £  PCR
buVer, and 0.04 U Titanium® polymerase (BD Bio-
Sciences, Clontech, CA, USA). Cycling conditions
were 94°C for 15 min, followed by 45 cycles of 94°C for
20 s, 56°C for 30 s and 72°C for 1 min, and then 72°C
for 3 min. Primer extension, sample clean up and
MALDI-TOF Mass Spectrometry analysis were per-
formed as described elsewhere (Whittaker et al. 2006).
Primer sequences are available on request.
Genotyping was carried out at a multiplex level of
four SNPs per well and data quality was assessed by
duplicate DNA (n = 4). SNPs with more than one dis-
crepant call or showing self-priming in the negative
control (water) were removed. Finally, we removed
non-polymorphic SNPs, SNPs with call rate below
70%, and markers that departed from Hardy Weinberg
equilibrium (P < 0.001).
Statistical analysis
Univariate and multiple analyses of predictor’s impact
on the square root of warfarin dose were calculated
using linear regression models as implemented by SAS
and SPLUS software. To account for partial depen-
dence among tests of SNPs in linkage disequilibrium
(LD), we applied both the Bonferroni correction for
multiple testing based on calculating the eVective num-
ber of independent tests (MeV) and a Permutation pro-
cedure (Cheverud 2001; Li 2001; Nyholt 2004). LD was
visualised using the HaploView software (Gabriel et al.
2002). The QTPHASE component of UNPHASED
software was used to estimate haplotype frequencies,
calculate means and variances of warfarin dose associ-
ated with each haplotype, and statistically test for
diVerences among the haplotype means (Dudbridge
2003). Pairwise LD was quantiWed by the standard r2
measure (Pritchard and Przeworski 2001). The propor-
tion of explained variance (coeYcient of determina-
tion) was measured by R2.123
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Association of warfarin dose with individual markers
We selected 29 candidate genes in the warfarin interac-
tive pathways (Fig. 1 and Supplementary Table S1) and
tested them for »800 SNPs that comprehensively cap-
tured common variation based on measures of LD
(r2 ¸ 0.8). In addition, we tested almost 100 functional
polymorphisms including several published variants
reported to be associated with warfarin dose, however,
most of the tested functional SNPs were later excluded
due to being monomorphic or having very low MAF.
We identiWed 348 SNPs (Supplementary Table S2) that
passed quality control and had a MAF of at least 4% in
our sample of 201 warfarin patients. Note that results
for VKORC1, GGCX and CYP2C9 are based on the
reanalysis of SNPs presented by Wadelius et al. (2005)
together with additional SNPs typed in this study. Uni-
variate regression analysis showed that 32 polymor-
phisms in or Xanking the genes VKORC1, CYP2C9,
CYP2C19, CYP2C18, PROC, EPHX1, CALU,
GGCX, ORM1 and ORM2 were nominally associated
with warfarin dose requirement (Table 1). In addition,
the two polymorphisms that discriminate between
APOE*E2, *E3 and *E4 were signiWcantly associated
with dose when assessed together (Table 1). In deter-
mining correction for multiple testing, we compared
the Permutation procedure with the Bonferroni correc-
tion based on the eVective number of independent
traits (Bonferroni MeV) and found that the two meth-
ods yielded very similar P-value cut-points (Cheverud
2001; Li 2001; Nyholt 2004). In this study, we present
the number of eVective tests within each gene obtained
by the Bonferroni MeV method. The number of inde-
pendent eVective tests within each gene or gene cluster
varied from 2 to 50, implying gene-wise corrected cut-
points of P < 0.025 to < 0.001. Assuming that the genes
are independent of each other, the sum of eVective
tests over all genes was 285. This makes P < 0.05/285,
which equals P < 0.000175, the cut-oV level for experi-
ment-wise signiWcance. Using this cut-point, VKORC1,
CYP2C9, CYP2C18 and CYP2C19, were associated
with dose after experiment-wise correction for multiple
testing, while PROC and APOE were signiWcant only
after within-gene correction (Table 1). Ten F2 SNPs,
41 F5 SNPs, 11 F7 SNPs, 11 F9 SNPs, 15 F10 15
SNPs, 13 PROZ SNPs, 11 PROS1 SNPs, four GAS6
SNPs, nine SERPINC1 SNPs, nine NQO1 SNPs, three
CYP1A1 SNPs, three CYP1A2 SNPs, two CYP3A4
SNPs, seven CYP3A5 SNPs, 12 CYP2C8 SNPs, 20
NR1I2 SNPs, nine NR1I3 SNPs and 38 ABCB1 SNPs
passed the study criteria, but none of them were signiW-
cantly associated with warfarin dose (Supplementary
Table S2).
Association of warfarin dose with haplotypes
Haplotype analysis showed 12 genes to be nominally
associated with warfarin dose (Table 2), namely
VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7,
GGCX, PROZ, F9, NR1I2 and ORM1-ORM2. Com-
pared with the univariate single-marker analysis, four
additional genes, F7, PROZ, F9 and NR1I2 were asso-
ciated at P < 0.05. The haplotypes that exhibited the
lowest P-values in each candidate gene are listed in
Table 2. VKORC1, CYP2C9, CYP2C18 and CYP2C19
showed experiment-wise signiWcance for haplotype
analysis, as they did for single markers. Likewise,
PROC was signiWcant at a gene-wise level.
Fine mapping of the VKORC1 and CYP2C regions
VKORC1 on chromosome 16 was the single gene most
strongly associated with warfarin dose (Tables 1, 2).
We previously described Wve SNPs in VKORC1 in an
extended region of high LD spanning over 300 kb in
the Swedish sample (Fig. 2). In this sample, three of the
SNPs (rs2359612, rs9934438, rs9923231) were perfectly
correlated with pairwise LD r2-values of »1.0 and
accounted for »30% of the warfarin dose variance (R2)
(Wadelius et al. 2005). An important goal of this study
was to Wne map VKORC1. Each of ten additional SNPs
in the VKORC1 region (Fig. 2a) was tested to deter-
mine if it added signiWcantly more dose variance to a
multiple regression model that included one of the
three linked SNPs (rs2359612), CYP2C9 *2 and *3, and
non-genetic predictors of warfarin dose (Supplemen-
tary Table S3). Our results demonstrated that: (a) each
of the three linked SNPs predicted more dose variance
(»30%) than any other genotyped VKORC1 SNP, and
(b) none of the other ten Xanking SNPs predicted addi-
tional dose variance (Fig. 2). In accordance, no
VKORC1 haplotype yielded association P-values more
signiWcant than the three linked SNPs (Tables 1, 2).
The molecular mechanism by which the three linked
SNPs inXuence warfarin response has not been
resolved. Due to the high LD between the three SNPs
in our population, it is not possible to discern which of
them that is responsible for the eVect on warfarin.
None of the studied SNPs are coding, and thus do not
alter protein structure. Instead the eVect may be medi-
ated by altering the amount of drug target in the liver
as postulated by studies showing that VKORC1 5
SNPs are correlated with liver levels of mRNA (Rieder
et al. 2005) and with activity in a reporter assay (Yuan123
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(Bodin et al. 2005).
The CYP2C gene cluster on chromosome 10 was the
second most strongly associated region after VKORC1
(Tables 1, 2). This region of high LD includes CYP2C9,
CYP2C8, CYP2C18 and CYP2C19 (Supplementary
Fig. S1). Several CYP2C SNPs were associated with
warfarin dose, even after correction for multiple test-
ing. The functional polymorphism in CYP2C9*3
(rs1057910, I359L), which severely impairs the capacity
to hydroxylate S-warfarin (Haining et al. 1996), was
the most strongly associated SNP in this region
(Table 1). The functional CYP2C9*2 polymorphism
(rs1799853, R144C) confers only a moderate reduction
in the metabolism of S-warfarin (Rettie et al. 1994),
and was not signiWcant in univariate analysis. In Wne
mapping of the CYP2C region, we successfully geno-
typed 53 additional SNPs: 17 in CYP2C9, ten in
CYP2C19, 14 in CYP2C18 and 12 in CYP2C8. In uni-
variate analysis, signiWcant association was observed
for nine SNPs apart from *3 including the CYP2C19 5
upstream rs3814637, the *15 allele and the intronic
Table 1 Genes with signiWcant association with warfarin dose, based on univariate regression of square root of dose
The SNPs are listed with the lowest P-value Wrst. The LD (r2 ) between the SNP with the lowest P-value and others in the gene or gene
cluster is shown. n is the number of successfully genotyped individuals
a Linkage disequilibrium with CYP2C9*3 (rs10579103)
b Note that the two APOE SNPs are not signiWcant individually, only when assessed as E2 + E4 vs. E3
*The test is signiWcant, based on correction for the eVective number of tests in each gene or gene cluster
**Corresponds to experiment-wise signiWcance, based on »285 independent eVective tests (P < 1.75 £ 10¡4 )
Gene SNP MAF n Univariate R2 P-Value r2 with best 
SNP
VKORC1 rs9923231 0.391 181 0.317 1.91 £ 10¡15** –
rs2359612 0.389 200 0.290 2.30 £ 10¡15** 0.968
rs9934438 0.383 169 0.292 3.59 £ 10¡13** 1.000
rs7294 0.384 188 0.208 4.14 £ 10¡10** 0.385
rs4889490 0.446 199 0.160 3.821 £ 10¡8** 0.461
rs4889537 0.372 199 0.142 3.158 £ 10¡7** 0.209
rs4889599 0.366 194 0.124 3.270 £ 10¡6** 0.305
rs8046978 0.214 197 0.047 0.00906 0.173
rs11642603 0.093 192 0.027 0.02304 0.070
rs11642466 0.103 195 0.025 0.02623 0.080
rs7194347 0.343 197 0.032 0.04069 0.153
CYP2C9 rs1057910 (*3) 0.058 201 0.141 2.784 £ 10¡7** –
rs9332108 0.064 201 0.141 2.784 £ 10¡7** 0.890
rs9325473 0.055 189 0.147 3.753 £ 10¡7** 0.908
rs1057911 0.067 191 0.145 4.218 £ 10¡7** 0.890
rs9332214 0.059 198 0.139 4.654 £ 10¡7** 0.878
rs4917639 0.173 197 0.118 4.944 £ 10¡6** 0.276
rs2860905 0.214 193 0.072 0.00080* 0.224
CYP2C19 rs3814637 0.059 195 0.106 0.00002** 0.838a
rs17882687(*15) 0.08 183 0.044 0.00417* 0.395a
CYP2C18 rs7896133 0.056 193 0.074 0.00013** 0.869a
PROC rs2069919 0.372 182 0.090 0.00022* –
rs1799809 0.433 188 0.078 0.00055* 0.777
rs2069901 0.441 177 0.072 0.00147* 0.785
rs2069910 0.387 178 0.046 0.01678 0.414
APOE rs429358 + rs7412b 0.251 201 0.051 0.00570* –
EPHX1 rs4653436 0.266 196 0.048 0.00848 –
CALU rs11653 0.366 197 0.047 0.00944 –
rs1006023 0.331 200 0.033 0.03789 0.865
rs2307040 0.336 200 0.033 0.03811 0.867
rs339054 0.461 195 0.032 0.04487 0.612
GGCX rs12714145 0.408 198 0.034 0.03320 –
ORM1-2 rs1687390 0.062 149 0.026 0.04964 –123
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allele, which leads to an inactive CYP2C19 enzyme,
was in agreement with earlier studies not associated
(Takahashi et al. 1998; Scordo et al. 2002). To test
whether any of the other CYP2C SNPs accounted for
additional dose variance, apart from the 2.4 and 10.9%
Table 2 Two or three marker haplotype giving the lowest P-value in each candidate gene
P-Values are arranged in ascending order and are based on QTPHASE haplotype test of association with square root of warfarin dose.
Genes not shown did not produce a nominally signiWcant (P < 0.05) haplotype result
a Yes indicates that the haplotype P-value is smaller than the P-value for the best single marker in the same gene
b Strongly associated with CYP2C9*3
c Strongly associated with CYP2C9*2
d GGCX microsatellite described by Chen at al. (2005)
*Gene-wise signiWcance based on correcting for the eVective number of tests in each gene. The other P-values are of nominal signiW-
cance (P < 0.05)
**Experiment-wise signiWcance (P < 1.75 £ 10¡4 )
Gene Haplotype P-value Smaller?a
VKORC1 rs9934438-rs9923231 5.76 £ 10¡15** No
CYP2C9 rs9332214b-rs9332222c-rs2298037 4.86 £ 10¡9** Yes
CYP2C18 rs1926711-rs7919273b-rs10509675 3.47 £ 10¡7** Yes
CYP2C19 rs2860840-rs3814637b 2.08 £ 10¡6** Yes
PROC rs2069919-rs2069921-rs973760 1.36 £ 10¡3* No
F7 rs3093229-rs3093233 2.42 £ 10¡2 Yes
GGCX Microsatellited-rs762684-rs6738645 1.78 £ 10¡2 Yes
PROZ rs2273971-rs3024711 3.57 £ 10¡2 Yes
F9 rs401597-rs392959 3.83 £ 10¡2 Yes
NR1I2 rs2461818-rs7643645 3.93 £ 10¡2 Yes
ORM1-2 rs1687390-rs3762055 4.93 £ 10¡2 No
Fig. 2 Fine mapping of the 
VKORC1 locus. a Location of 
SNP markers (MAF ¸ 5%) in 
a »550 kb region surrounding 
VKORC1 which is coded on 
the reverse strand and is locat-
ed at the right end of the LD 
block. Previously reported 
SNPs are shown in red (11). 
b The univariate r2 (pink, left 
axis) and P-value (blue, right 
axis) are shown for each SNP. 
The black line near 10¡3 on 
the right axis indicates the 
P-value that is necessary to 
achieve signiWcance after 
within-gene Bonferroni cor-
rection. c HaploView analysis 
with pair-wise r2 illustrating 
the extent of LD in the region. 
The red dotted triangle indi-
cates the LD block deWned 
with data of the HapMap pro-
ject (CEU panel)123
30 Hum Genet (2007) 121:23–34explained by CYP2C9*2 and *3, two multiple regres-
sion models were used (Table 3). Both models contained
VKORC1 (rs2359612) and signiWcant non-genetic
predictors of warfarin dose, whereas one contained
CYP2C9*2 but not *3 and vice versa. Each one of the
55 CYP2C SNPs was evaluated against the two
multiple regression models. This showed that except
for the CYP2C9 SNP rs4917639, all signiWcant results
were fully explained by LD with either CYP2C9*2 or
*3. In contrast, CYP2C9 SNP rs4917639 gave a signiW-
cant P-value in both the *2 model (P < 1.33 £ 10¡9)
and the *3 model (P < 3.56 £ 10¡3). The minor allele of
rs4917639 was in perfect LD (r2 = 1) with a composite
minor allele formed by aggregating CYP2C9*2 and *3
into a single allele, although *2 and *3 are rarely car-
ried on the same haplotype (McGinnis et al. 2006).
These data suggest that the rs4917639 mutation
occurred Wrst, and that rs1799853 and rs1057910, which
are diagnostic for *2 and *3, arose independently on
the same parent allele. The strong association between
rs4917639 and *2/*3 could perhaps be due to positive
selection, if rs4917639 lessened the deleterious eVect of
impaired CYP2C9 metabolism caused by *2 and *3.
This and related possibilities merit further investiga-
tion given the unusual pattern of LD between
rs4917639 and *2/*3.
Other genes tentatively associated with warfarin dose
Of the 13 PROC SNPs included in the analysis, four
were signiWcantly associated with dose: rs1799809
A > G and rs2069901 T > C in the 5 regulatory region
of PROC, rs2069910 C > T in intron 2 and rs2069919
G > A in intron 3 (Table 1). The two promoter poly-
morphisms and the intron 3 polymorphism reached
gene-wise signiWcance and explained 7–9% of the vari-
ance in warfarin dose; P = 0.0002–0.0015. Haplotypes
of PROC were also signiWcantly associated with dose,
but did not increase the statistical conWdence since the
lowest P-value was 0.00136 (Table 2). Unlike most
other vitamin K-dependent factors, protein C acts as a
natural anticoagulant by inactivating factors Va and
VIIIa, but all its activities are not yet fully understood
(Dahlbäck 2005). Intriguingly, it has previously been
shown that protein C activity is negatively correlated
with PT INR, not only in patients treated with oral
anticoagulants, but also in healthy subjects and in med-
ical patients without oral anticoagulants (Watala et al.
2003). Two other studies have found that homozygos-
ity for the G allele of the PROC promoter polymor-
phism rs1799809 is associated with slightly reduced
concentrations and activities of protein C (Spek et al.
1995; Aiach et al. 1999). In our study, carriers of
Table 3 SigniWcant (P < 0.05) regression results for SNPs in the CYPC2 gene cluster
Additional dose variance (R2 ) explained by each SNP and the corresponding P-value is shown for two multiple regression models of
warfarin dose. Both models contain VKORC1 SNP rs2359612 and non-genetic predictors identiWed by Wadelius et al. (2005).
CYP2C9*2 is included in the Wrst alternative regression model and CYP2C9*3 is included in the second model. A non-signiWcant
P-value for the *2 model but highly signiWcant result for the *3 model implies that *2 fully accounts for the tested SNP’s contribution to
dose variance (and vice versa). Thus, *2 or *3 fully account for each tested SNP apart from rs4917639
SNPs giving non-signiWcant (P > 0.05) results in both models are: CYP2C8 (rs2275622, rs7898759, rs1557044, rs2275620, rs1341163,
rs1891071, rs1058932, rs1058930, rs947173, rs17110453, rs3752988); CYP2C9 (rs9332197, rs2475376, rs1856908, rs1934964, rs2153628,
rs10509679, rs2298037); CYP2C18 (rs10736086, rs10509675, rs12249418, rs7099637, rs7898763, rs7919273, rs1926706, rs2281891,
rs1926711, rs7478002, rs2860837, rs2860840); CYP2C19 (rs4244284, rs12248560, rs3758580, rs4250786, rs17879456, rs17882419,
rs4417205, rs1853205)
Gene SNP R2 with *2 model P-Value R2 with *3 model P-Value
CYP2C8 rs11572080 0.001 0.502 0.017 0.005
CYP2C9 rs9332108 0.109 1.57 £ 10¡10 0.000 0.999
CYP2C9 rs1057910 (*3) 0.109 1.57 £ 10¡10 – –
CYP2C9 rs1057911 0.114 2.97 £ 10¡10 0.000 0.999
CYP2C9 rs9325473 0.112 5.45 £ 10¡10 0.000 0.999
CYP2C9 rs4917639 0.100 1.33 £ 10¡9 0.025 3.56 £ 10¡3
CYP2C9 rs9332214 0.098 1.50 £ 10¡9 0.000 0.999
CYP2C9 rs2860905 0.048 1.86 £ 10¡4 0.009 0.153
CYP2C9 rs4917636 0.004 0.213 0.026 3.63 £ 10¡3
CYP2C9 rs4607998 0.004 0.252 0.026 2.85 £ 10¡3
CYP2C9 rs1799853 (*2) – – 0.024 4.00 £ 10¡3
CYP2C9 rs1934966 0.000 0.999 0.015 8.72 £ 10¡3
CYP2C9 rs9332222 0.000 0.999 0.025 3.86 £ 10¡3
CYP2C18 rs7896133 0.063 5.17 £ 10¡7 0.000 0.999
CYP2C18 rs2901783 0.020 0.029 0.004 0.471
CYP2C19 rs3814637 0.098 3.76 £ 10¡9 0.000 0.896
CYP2C19 rs17882687 0.047 5.19 £ 10¡5 0.000 0.828123
Hum Genet (2007) 121:23–34 31rs1799809 G/G, had lower dose requirements than oth-
ers (P = 0.00055). If rs1799809 G/G individuals have a
reduced pre-treatment protein C activity (Spek et al.
1995; Aiach et al. 1999), which according to Watala
et al. (2003) is associated with higher PT INR, then this
might explain their low-warfarin dose requirements.
However, this theory needs to be tested in a larger
population. A Japanese group previously failed to Wnd
an association between warfarin dose and the rare syn-
onymous coding PROC SNP rs5935 (Shikata et al.
2004), which was not polymorphic in our sample.
We analysed the two APOE SNPs that deWne the
widely used *E2, *E3 and *E4 allelic system. Patients
who carried the common allele *E4 or the rarer *E2
required higher warfarin doses than those with *E3;
P = 0.0057. This result was signiWcant after within-gene
correction for multiple testing (Table 1). We previ-
ously reported that CYP2C9 extensive metabolisers
who were homozygous for APOE*E4 required higher
warfarin doses than other extensive metabolisers;
P = 0.0008 (Kohnke et al. 2005b). This is supported by
a Dutch study that found slightly higher maintenance
doses of the anticoagulant phenprocoumon in
APOE*E4 homozygous individuals (Visser et al.
2005). Surprisingly, the same study found that
APOE*E4 carriers required lower maintenance doses
of acenocoumarol. No homozygous *E4 individuals
were found among Italian patients, and the association
between warfarin dose requirements and APOE geno-
type was not seen (Kohnke et al. 2005a). These dis-
crepant results indicate that the association between
anticoagulant dose and APOE, if any, is weak. In addi-
tion, they point out that a future warfarin dose predic-
tion model may not be applicable to phenprocoumon
and acenocoumaron.
Nine other genes were nominally associated with
warfarin dose, but did not pass correction for multiple
testing: GGCX, F7, PROZ, F9, EPHX1, CALU,
NR1I2, ORM1 and ORM2 (Tables 1, 2). It has been
shown that warfarin dose tends to increase with the
number of repeats of a microsatellite in intron 6 of
GGCX (Shikata et al. 2004; Chen et al. 2005). A haplo-
type including the microsatellite was more signiWcant
than the intron 2 SNP rs12714145 reported by Chen
et al. (2005), however, both failed to reach gene-wise
signiWcance (Tables 1, 2). The SNP rs5896 causing a
threonine to methionine change at position 165 in the
prothrombin gene (F2), which was reported to confer
warfarin sensitivity (D’Ambrosio et al. 2004; Shikata
et al. 2004), did not replicate in our study; P = 0.2923.
F7, F10 and PROZ are positioned in close proximity,
and F7 promoter polymorphisms are claimed to have
an eVect on warfarin sensitivity (D’Ambrosio et al.
2004; Shikata et al. 2004; Aquilante et al. 2006). A hap-
lotype located 2 kb upstream of F7 was tentatively
associated with dose, and so was a PROZ haplotype
comprising SNPs 5 upstream of the gene and in the
Wrst intron (Table 2). On the other hand, the coding F7
SNP rs6046 (R413Q, formerly R353Q) that may lead
to decreased plasma levels of factor VII (Arbini et al.
1994), and the synonymous SNP rs5960 in the exon 7 of
F10 did not aVect warfarin dosing (Shikata et al. 2004).
The rare variant in F9 (A-10V/T) that causes a dispro-
portional reduction in factor IX activity in warfarin-
treated patients (Kristensen 2002; van der Heijden
et al. 2004) was not found in our study population,
although a haplotype covering this region showed
nominal association to dose (Table 2). A recent study
has shown an association between high doses of warfa-
rin in CYP2C9 extensive metabolisers carrying the
non-synonymous EPHX1 SNP rs1051740 which results
in a tyrosine to histidine substitution at residue 113
(Loebstein et al. 2005). We failed to replicate this Wnd-
ing, although rs4653436 located 5 upstream was nomi-
nally associated with dose (Table 1). A coding SNP in
CALU (R4Q), that is suspected to increase warfarin
dose requirement in CYP2C9 and VKORC1 wild type
patients (Vecsler et al. 2006), was not signiWcantly asso-
ciated with dose in our study. However, the 3 UTR
CALU SNP rs11653, the non-synonymous rs2307040
and the two intronic rs339054 and rs1006023 gave bor-
derline signiWcant P-values (Table 1). The nominal
association between warfarin dose requirements and a
haplotype of NR1I2 has to our knowledge not previ-
ously been shown (Table 2). Warfarin’s association
with rs3762055 located between ORM1 and ORM2,
and with a haplotype covering this region are also
novel Wndings (Tables 1, 2). The weaker associations
observed for these tentatively associated genes require
testing and validation in an independent and larger
data set. Finally, it is worth mentioning that the pro-
thrombotic F5 Leiden variant (rs6025) had no eVect on
warfarin dose requirement in our study (P = 0.4925).
Multiple modelling
To explore the potential of a warfarin dose prediction
model, we combined the genes with the largest impact
on warfarin dose (VKORC1, CYP2C9 and PROC)
with patient characteristics (age, bodyweight, interac-
tion with other drugs and indication for treatment) in a
multiple regression model. This model explained 62%
of the variance in dose. We then considered all nomi-
nally associated genes, VKORC1, CYP2C9, CYP2C19,
CYP2C18, PROC, APOE, EPHX1, CALU, GGCX
and ORM1-2 in a model, which explained 76% of the123
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with individual P-values above 0.2 and a low-explana-
tory value (R2) were subsequently removed from the
model in a stepwise manner. We Wnally reached a
model containing VKORC1, CYP2C9*2 and *3,
PROC, EPHX1, GGCX, ORM1-2, age, bodyweight
and drug interactions which explained 73% of the vari-
ance in warfarin dose (Table 4). However, this specula-
tive model requires validation in a large independent
sample of warfarin patients.
Conclusion
VKORC1, CYP2C9, CYP2C19, CYP2C18, PROC and
APOE were all signiWcantly associated with warfarin
dose after correction for multiple testing. Three linked
VKORC1 SNPs and the CYP2C9 allele *3 were the
strongest genetic factors determining warfarin dose
requirements. We Wne mapped the VKORC1 and
CYP2C regions in search of polymorphisms that might
explain additional dose variance in our Swedish study
population. However, none of the VKORC1 SNPs or
haplotypes accounted for more dose variance than the
three linked SNPs. Likewise, no CYP2C polymorphism
contributed more to dose variance than CYP2C9*2 or
*3. Apart from VKORC1 and CYP2C9, the most sig-
niWcant Wnding was the association of SNPs in PROC
that reached gene-wise signiWcance. Although factors
II, VII and X have the strongest inXuence, it has been
shown that protein C, the product of the PROC gene,
has an eVect on one of the outcome parameters of the
current study, i.e. the prothrombin time (Watala et al.
2003). If genetic variation in PROC inXuences the pro-
thrombin time, which in turn determines the required
warfarin dose, it is not improbable that genetic varia-
tion in PROC plays a role for warfarin dose. Further-
more, as previously reported, CYP2C9 extensive
metabolisers who were homozygous for APOE*E4
required higher warfarin doses than others (Kohnke
et al. 2005b). Replication in a larger patient cohort will
ascertain whether PROC and APOE are true determi-
nants of warfarin dosing.
With this systematic warfarin study, we can explain
62% of the variance in warfarin dose in Swedish
patients by using a multiple regression model of
VKORC1, CYP2C9*2/*3, PROC and non-genetic fac-
tors. The addition of EPHX1, GGCX and ORM1-2, to
the model predicts an extra »10% of the variance.
However, this model requires further validation in
independent and larger samples, and will be tested in
the WARG (http://www.druggene.org/) cohort of 1,500
Swedish warfarin treated patients. Even so, this future
model will only be applicable for patients of European
ancestry, and similar studies need to be performed in
other ethnic groups. When all common alleles contrib-
uting to warfarin response have been identiWed in the
major ethnic groups, a comprehensive dose model that
is applicable regardless of ethnicity can be developed.
Dosing models may subsequently be translated into
clinical guidelines for warfarin prescription, and could
have a major impact on the safety and eYcacy of war-
farin.
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